News | Breast Imaging | March 02, 2017

Volpara Solutions Showcases Volpara Enterprise 2.0 Software at ECR 2017

Research presented at ECR demonstrates how software helps breast imaging providers deliver high-quality, personalized breast screening

Volpara Solutions, Volpara Enterprise 2.0 software, breast imaging, screening, ECR 2017

March 2, 2017 — Volpara Solutions announced the European launch of Volpara Enterprise 2.0 software, which helps breast imaging facilities deliver high-quality, personalized breast screening. The software was launched at the European Congress of Radiology (ECR) meeting, March 1-5, 2017, in Vienna, Austria.

Volpara Enterprise software delivers key performance indicators (KPIs) for hundreds of performance and quality metrics, including patient positioning, compression and equipment utilization. The software provides continuous quality assurance and performance monitoring through dynamic, interactive dashboards, feeding ConstantQuality metrics that are updated with every mammography or tomosynthesis (3-D mammography) exam. The Microsoft Azure-based solution is fully integrated with VolparaDensity software.

Designed to support large or small enterprises, Volpara Enterprise software enables breast centers to perform rapid quality control checks that help optimize the productivity and efficiency of imaging resources. This in turn helps decrease costs through the reduction of retakes, increases employee effectiveness and enhances the patient experience.

Updates to VolparaEnterprise 2.0 software include:

  • New infographics and analytics tools to help improve understanding of resource utilization and performance and provide better understanding of the patient population and referral patterns;
  • The new technologist dashboard enables each radiographer to monitor her own performance and self-train to fix positioning and compression problems;
  • The lead radiographer now sees a Quality Quadrant diagram that summarizes patient positioning and compression performance by each radiographer, helping to identify training opportunities; and
  • The broader use of infographics on each new role-specific landing page makes data quicker and easier to summarize and interpret. 

“Adding VolparaEnterprise software has enabled us to implement new quality processes that will help ensure that every woman’s mammogram is the best that we can offer. Being able to pull data that has been hidden, we’re able to improve the practice’s efficiencies and effectiveness, which will help improve outcomes. We owe that to our patients,” said Kathy Schilling, M.D., medical director, Boca Raton Regional Hospital’s Christine E. Lynn Women’s Health & Wellness Institute in Florida.

Volpara Solutions is showcasing its entire suite of quantitative breast imaging tools at ECR.

The ability of analytics data from VolparaEnterprise software to help maintain accuracy and consistent quality in breast screening is the focus of numerous abstracts and educational sessions accepted for presentation at the ECR, including:

  • “Large variation in mammography compression internationally.” This poster presents an overview of breast compression across 15 countries from Australasia, Europe, and North and South America. There is a wide variation in compression between countries, which may arise both from patient-specific differences and disparities in the compression behavior of the technologists. Standardized monitoring of compression, such as done with VolparaEnterprise, can help to reduce such discrepancies, according to the company;
  • “Determination of adequate breast tissue visualisation using an automated posterior nipple line measure.” This poster describes automated measurement of the posterior nipple line (PNL). Good breast positioning is crucial for optimal cancer detection, but difficult to assess manually. The automated method proved robust in comparison to gold-standard manual measurement of the PNL and provides an important quality metric to monitor operator performance; and
  • “Grade, size, invasive status and breast density of screen-detected and interval cancers in breast screening in the U.K.”  This analysis of 3,771 U.K. women reveals that women presenting with interval cancers have a Volpara Density Grade that is 2.1 percent higher than women with screen-detected cancers. Interval cancers arise between regular mammography exams and tend to be aggressive and have a poor prognosis. Interval cancers also prove to be of higher grade, larger size and are more likely to be invasive, according to the study.

For more information: www.volparasolutions.com

Related Content

Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow
Technology | Mammography | December 11, 2017
Siemens Healthineers unveiled the new Mammomat Revelation premium mammography platform at the 2017 Radiological Society...
Breast Cancer Screening Performance Impacted by Mean Mammographic Compression Pressure
News | Mammography | December 08, 2017
Dutch researchers demonstrated a strong relationship between compression pressure in mammography and breast cancer...
Sponsored Content | Videos | Mammography | December 06, 2017
Martin Yaffe, Ph.D., FAAPM, senior scientist, physical sciences/imaging research, Sunnybrook Health Sciences Centre,
Ikonopedia and Konica Minolta Showcase Integrated Breast Imaging Workflow and Reporting at RSNA
News | Breast Imaging | December 05, 2017
Ikonopedia and Konica Minolta Healthcare Americas Inc. showcased integrated breast imaging workflow and reporting at...
Sponsored Content | Videos | Breast Imaging | December 05, 2017
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, attending radiologis
Numerous Studies Highlight Importance of Quantitative Breast Imaging Analysis at RSNA 2017
News | Breast Density | November 30, 2017
The importance of quantitative analysis in breast imaging was the focus of numerous abstracts accepted for presentation...
Hologic Receives FDA 510(k) Clearance of Quantra 2.2 Breast Density Assessment Software
Technology | Breast Density | November 28, 2017
Hologic Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its...
Eizo RadiForce RX560 Monitor Receives FDA 510(k) for Tomosynthesis and Digital Mammography
Technology | November 20, 2017
Eizo Corp. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for breast tomosynthesis...
Biop Medical Launches Cervical Cancer Diagnosis Technology at MEDICA 2017

Biop Medical cervical cancer detection system

Technology | Women's Health | November 13, 2017
November 13, 2017 — Biop Medical announced it will present its point-of-care...
Overlay Init